美国食品和药物管理局关于婴儿配方"行动速度"的专家小组 2025年6月:第二部分,监管和安全考虑
Steven A Abrams1, J Thomas Brenna1, Roger Clemens2
1Department of Pediatrics, Dell Medical School at the University of Texas, Austin, TX, United States.
Advances in nutrition (Bethesda, Md.)
|January 22, 2026
概括
"子速度行动"旨在改善婴儿配方奶粉监管. 该研究强调需要更新法规,供应链透明度和全球安全标准的调整,以解决配方安全和市场准入问题.
科学领域:
- 食品科学与技术 食品科学与技术
- 公共卫生政策 公共卫生政策
- 监管事务 监管事务
背景情况:
- 最近婴儿配方奶粉短缺和安全问题促使"子速度行动".
- 目前食品和药物管理局 (FDA) 对婴儿配方奶粉的规定是复杂的,并且进入市场的速度很慢.
- 现有的途径,如一般公认的安全 (GRAS),对新成分的批准有限制.
研究的目的:
- 分析目前美国婴儿配方奶粉的监管环境.
- 确定新婴儿配方奶粉和原料的批准过程中的挑战.
- 评估婴儿配方奶粉中毒物质相关的风险,并将美国标准与国际基准标准进行比较.
主要方法:
- 对婴儿配方奶粉的FDA监管流程的审查.
- 对GRAS和食品添加剂申请途径的分析.
- 美国婴儿配方奶粉法规与欧盟,加拿大和澳大利亚的法规进行比较.
- 检查婴儿配方中重金属,PFAS和其他毒素的安全问题.
主要成果:
- 美国食品和药物管理局的流程可能是缓慢而复杂的,阻碍了新配方药的进入市场.
- GRAS和食品添加剂路径需要安全数据,食品添加剂请愿需要广泛的FDA批准.
- 婴儿配方奶粉可能含有重金属和PFAS等有毒物质,对婴儿构成风险.
- 与其他主要市场不同,美国对这些毒素缺乏可执行的限制.
结论:
- 立法更新是必要的,以现代化婴儿配方奶粉监督.
- 增加供应链透明度对于确保配方安全和可用性至关重要.
- 需要与国际安全标准保持一致,以加强美国婴儿配方奶粉监管环境.
相关概念视频
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
01:29Clinically Relevant Drug Product Specifications: Methods of Establishment
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
01:29Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).